Catheter Precision Receives Notification of New Patent Issuance for VIVO Product Line
Catheter Precision (NYSE:VTAK), a medical device company specializing in cardiac electrophysiology products, has received notification for a new patent issuance from the U.S. Patent and Trademark Office. The patent, titled "Methods of Ventricular Arrhythmia Localization Using a 3D Heart Model," enhances the company's VIVO product line.
The new patent adds to Catheter Precision's existing IP portfolio for VIVO, which is designed to help physicians identify ventricular arrhythmias noninvasively before procedures. CEO David Jenkins emphasized the importance of patents and trademarks in their business strategy and their commitment to advancing medical technology for improved patient care.
Catheter Precision (NYSE:VTAK), azienda di dispositivi medici specializzata in prodotti per l'elettrofisiologia cardiaca, ha ricevuto comunicazione dall'Ufficio Brevetti e Marchi degli Stati Uniti dell'emissione di un nuovo brevetto. Il brevetto, intitolato "Methods of Ventricular Arrhythmia Localization Using a 3D Heart Model", potenzia la linea di prodotti VIVO dell'azienda.
Questo nuovo brevetto si aggiunge al portafoglio di proprietà intellettuale di Catheter Precision relativo a VIVO, progettato per aiutare i medici a identificare in modo non invasivo le aritmie ventricolari prima degli interventi. Il CEO David Jenkins ha sottolineato l'importanza di brevetti e marchi nella strategia aziendale e il loro impegno nello sviluppo di tecnologie mediche per migliorare la cura dei pazienti.
Catheter Precision (NYSE:VTAK), una compañía de dispositivos médicos especializada en productos de electrofisiología cardíaca, ha recibido una notificación de la Oficina de Patentes y Marcas de Estados Unidos sobre la concesión de una nueva patente. La patente, titulada "Methods of Ventricular Arrhythmia Localization Using a 3D Heart Model", refuerza la línea de productos VIVO de la empresa.
Esta nueva patente se suma al portafolio de propiedad intelectual de Catheter Precision para VIVO, diseñado para ayudar a los médicos a identificar arritmias ventriculares de forma no invasiva antes de los procedimientos. El CEO David Jenkins destacó la relevancia de las patentes y marcas en la estrategia empresarial y su compromiso con el avance de la tecnología médica para mejorar la atención al paciente.
Catheter Precision (NYSE:VTAK)는 심장 전기생리학 제품을 전문으로 하는 의료기기 회사로, 미국 특허청(USPTO)으로부터 신규 특허 발급 통지를 받았습니다. "Methods of Ventricular Arrhythmia Localization Using a 3D Heart Model"라는 제목의 이 특허는 회사의 VIVO 제품군을 강화합니다.
이번 특허는 시술 전 의사가 비침습적으로 심실성 부정맥을 식별할 수 있도록 설계된 VIVO 관련 Catheter Precision의 기존 지식재산 포트폴리오에 추가됩니다. CEO 데이비드 젠킨스는 특허와 상표가 회사 전략에서 차지하는 중요성과 환자 치료 향상을 위한 의료기술 발전에 대한 의지를 강조했습니다.
Catheter Precision (NYSE:VTAK), une entreprise de dispositifs médicaux spécialisée dans les produits d'électrophysiologie cardiaque, a reçu une notification de l'Office des brevets et des marques des États-Unis concernant la délivrance d'un nouveau brevet. Le brevet, intitulé "Methods of Ventricular Arrhythmia Localization Using a 3D Heart Model", renforce la gamme de produits VIVO de la société.
Ce nouveau brevet vient s'ajouter au portefeuille de propriété intellectuelle de Catheter Precision pour VIVO, conçu pour aider les médecins à identifier de manière non invasive les arythmies ventriculaires avant les interventions. Le PDG David Jenkins a souligné l'importance des brevets et des marques dans la stratégie de l'entreprise et son engagement à faire progresser la technologie médicale pour améliorer les soins aux patients.
Catheter Precision (NYSE:VTAK), ein Medizintechnikunternehmen, das sich auf Produkte der kardialen Elektrophysiologie spezialisiert hat, hat eine Mitteilung vom US-Patent- und Markenamt über die Erteilung eines neuen Patents erhalten. Das Patent mit dem Titel "Methods of Ventricular Arrhythmia Localization Using a 3D Heart Model" stärkt die VIVO-Produktlinie des Unternehmens.
Das neue Patent ergänzt das bestehende geistige Eigentum von Catheter Precision für VIVO, das darauf ausgelegt ist, Ärzten zu helfen, ventrikuläre Arrhythmien vor Eingriffen nichtinvasiv zu identifizieren. CEO David Jenkins betonte die Bedeutung von Patenten und Marken in der Unternehmensstrategie sowie das Engagement für die Weiterentwicklung medizinischer Technologien zur Verbesserung der Patientenversorgung.
- New patent strengthens IP portfolio for VIVO product line
- Technology enables noninvasive identification of ventricular arrhythmias
- Expands capabilities in cardiac electrophysiology market
- None.
Fort Mill, S.C., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that it has received notification from the Unites States Patent and Trademark Office for issuance of a new a VIVO patent titled Methods of Ventricular Arrhythmia Localization Using a 3D Heart Model. This patent is in addition to several already granted patents for VIVO.
David Jenkins, CEO of Catheter Precision, said, “Patents and trademarks are an integral part of our business activities. We strive for VIVO to be used as a tool to easily identify ventricular arrhythmias noninvasively and provide the physician with additional information before the procedure. This new patent allows us to continue advancing methods of identification and providing physicians with the information they need to successfully treat patients while adding to our growing IP portfolio.”
About VIVO™
Catheter Precision’s VIVO (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE Mark.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS:
Investor Relations
973-691-2000
IR@catheterprecision.com
# # #
FAQ
What new patent did Catheter Precision (VTAK) receive in August 2025?
What is the purpose of VTAK's VIVO technology?
How does the new patent benefit Catheter Precision's business?
Who is the CEO of Catheter Precision (VTAK)?
